Format

Send to

Choose Destination
Expert Opin Pharmacother. 2008 Sep;9(13):2377-82. doi: 10.1517/14656566.9.13.2377 .

Biphasic insulin aspart 30 for the treatment of type 1 diabetes mellitus.

Author information

1
University of Tennessee Health Science Center and the University of Tennessee Lifestyle Diabetes and Obesity Center, Department of Pediatrics, Memphis, TN 38103, USA. pvelasquez@utmem.edu

Abstract

BACKGROUND:

Type 1 diabetes mellitus is associated with acute and long-term complications, to which pre- and postprandial hyperglycemia are independent contributors. The objective of this review was to evaluate evidence-based information using biphasic insulin aspart 30 in the treatment of type 1 diabetes mellitus.

METHODS:

The study reviewed the Cochrane Database and scientific literature (PubMed) published until January 2008 using the words biphasic insulin aspart 30 insulin or premixed aspart insulin.

CONCLUSIONS:

Biphasic insulin aspart 30 is similar in efficacy to biphasic human insulin in improving hemoglobin A(1c) levels, with the advantage of a better postprandial glucose profile.

EXPERT OPINION:

There is evidence supporting the efficacy and safety of biphasic insulin aspart 30 insulin. However, the need for well-designed clinical trials aimed at understanding the potential differences in safety and efficacy between patients with type 1 and type 2 diabetes is crucial.

PMID:
18710361
DOI:
10.1517/14656566.9.13.2377
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center